Sboll is Your Go-to Source for the Latest Finance News, Covering Markets, Banking, Investments, Economy and Stocks.
⎯ 《 Sboll • Com 》

ZAP Surgical Announces Upcoming Installation of Novel Non-Invasive Brain Tumor Treatment System in South Korea

2023-06-13 19:22
SAN CARLOS, Calif.--(BUSINESS WIRE)--Jun 13, 2023--
ZAP Surgical Announces Upcoming Installation of Novel Non-Invasive Brain Tumor Treatment System in South Korea

SAN CARLOS, Calif.--(BUSINESS WIRE)--Jun 13, 2023--

ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that Dankook University Hospital (DKUH) in Cheonan, South Korea, is slated to install the novel ZAP-X® Gyroscopic Radiosurgery® platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230613005017/en/

ZAP-X® Gyroscopic Radiosurgery® platform (Photo: Business Wire)

DKUH is the largest general hospital in Chungnam Province with 900 patient beds and 33 specialty clinics and was selected as the Chungnam Regional Cancer Center by the Ministry of Health and Welfare. The new oncology diagnosis and treatment facility is the only cancer center in the region. With the addition of ZAP-X, DKUH will provide the latest advance in brain tumor care to patients throughout the country.

Stereotactic radiosurgery (SRS) offers a non-invasive and painless treatment for many primary and metastatic brain tumors, as well as other cranial disorders such as trigeminal neuralgia and arteriovenous malformations (AVM). For select indications, radiosurgery has proven to provide equivalent to superior outcomes compared to costly and potentially debilitating surgeries. SRS is typically delivered in one to five brief outpatient visits and patients often return to normal activity the same day as the procedure.

“We look forward to introducing the newest, most advanced radiosurgical technology to the Korean market,” said Dr. Lee Sang Koo, Vice President of DKUH, Neurosurgery. “As the sole cancer center in the Chungnam region, we play an important role in the treatment of brain tumors. The integration of ZAP-X will allow us to deliver state-of-the-art treatment to the patients we serve.”

With its ground-breaking design, the ZAP-X system uses unique gyroscopic mobility to direct radiosurgical beams from hundreds of unique angles to precisely concentrate radiation on the tumor target. This pioneering approach supports the clinical objective of protecting healthy brain tissue and preserving patient cognitive function.

The vault-free, cobalt-free ZAP-X is also renowned for eliminating the expense of building costly shielded radiation treatment rooms, and removing the need to maintain, secure and regularly replace live radioactive isotopes for radiation beam production.

About ZAP Surgical Systems, Inc.

ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® Gyroscopic Radiosurgery® platform. ZAP was founded in 2014 by Dr. John R. Adler. In addition to being CEO of ZAP, Dr. Adler is Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. Dr. Adler is also renowned as the inventor of the CyberKnife ® system and founder of Accuray, Inc. The ZAP-X platform incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms. ZAP-X also utilizes a modern linear accelerator to eliminate legacy use of Cobalt-60. Learn more at ZAP Surgical and follow us on LinkedIn and Twitter.

View source version on businesswire.com:https://www.businesswire.com/news/home/20230613005017/en/

CONTACT: Mark Arnold, ZAP Surgical Systems, Inc.

Senior Vice President, Marketing

+1 650 492 7797, ext. 101

Email:info@zapsurgical.com

KEYWORD: SOUTH KOREA UNITED STATES NORTH AMERICA ASIA PACIFIC CALIFORNIA

INDUSTRY KEYWORD: NEUROLOGY RADIOLOGY SURGERY ONCOLOGY HEALTH MEDICAL DEVICES HOSPITALS HEALTH TECHNOLOGY

SOURCE: ZAP Surgical Systems, Inc.

Copyright Business Wire 2023.

PUB: 06/13/2023 07:15 AM/DISC: 06/13/2023 07:16 AM

http://www.businesswire.com/news/home/20230613005017/en